Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Nov 26:7:852.
doi: 10.1186/1756-0500-7-852.

Delayed-onset flaccid paralysis related to west Nile virus reactivation following treatment with rituximab: a case report

Asaf Honig, Dimitrios Karussis  1
Affiliations
Case Reports

Delayed-onset flaccid paralysis related to west Nile virus reactivation following treatment with rituximab: a case report

Asaf Honig et al. BMC Res Notes. .

Abstract

Background: Neurological manifestations of West Nile virus infection include meningitis, encephalitis and acute flaccid paralysis. Typically, West Nile virus-associated acute flaccid paralysis is characterized by acute and rapidly progressing limb weakness, occurring early in the course of the disease.

Case presentation: We report a patient of Yemenite descent who developed West Nile virus-encephalitis and poliomyelitis two weeks following treatment with rituximab for B cell lymphoma, and delayed encephalitis with ascending demyelinating polyneuropathy 6 months later. Diagnosis of the first episode was based on a high West Nile virus copy number in the blood polymerase chain reaction. During the second episode the patient developed encephalitis and flaccid asymmetric quadriparesis, accompanied by high IgM anti-West Nile virus titers in the blood and cerebrospinal fluid.

Conclusion: The delayed polyneuropathy post-West Nile virus infection and encephalitis/poliomyelitis may be related to reactivation of the virus or to a delayed autoimmune (post-infectious) process, possibly accelerated by the recovering B-cell humoral immunity, 6 months after treatment with rituximab. This case depicts the complexities of the immune responses and their reconstitution following monoclonal antibody treatment and the diversity of neurological syndromes associated with West Nile virus infection.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Mostashari F, Bunning M, Kitsutani P, Singer D, Nash D, Cooper M, Katz N, Liljebjelke K, Biggerstaff B, Fine A, Layton M, Mullin S, Johnson A, Martin D, Hayes E, Campbell G. Epidemic West Nile Encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 1999;2001(358):261–264. - PubMed
    1. Sejvar J, Davis L, Szabados E, Jackson A. Delayed-onset and recurrent limb weakness associated with West Nile virus infection. J Neurovirol. 2010;16(1):93–100. doi: 10.3109/13550280903586378. - DOI - PubMed
    1. Murray K, Walker C, Herrington E, Lewis J, Mccormick J, Beasley D, Tesh R, Fisher-Hoch S. Persistent Infection with West Nile virus years after initial infection. J Infect Dis. 2010;201(1):2–4. doi: 10.1086/648731. - DOI - PMC - PubMed
    1. Jaso R, Sierra M, Calleja J, Valero C, Pascual J. Guillain-Barré Syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association? J Neurol. 2010;257(3):488–489. doi: 10.1007/s00415-009-5400-3. - DOI - PubMed
    1. Terenghi F, Ardolino G, Nobile-Orazio E. Guillain-Barré syndrome after combined chop and rituximab therapy in non-Hodgkin lymphoma. J Peripher Nerv Syst. 2007;12:142–143. doi: 10.1111/j.1529-8027.2007.00134.x. - DOI - PubMed

Publication types

MeSH terms

Substances